![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Presents New Data on Its Defensin-Mimetic Antibiotics at 52nd Annual ICAAC
September 11, 2012 16:15 ET
|
PolyMedix, Inc.
RADNOR, Pa., Sept. 11, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
Data Showing Effectiveness of PolyCide Antimicrobial in Surgical Suture Coatings Published in American Chemical Society Journal, Langmuir
September 05, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Sept. 5, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative approaches to transforming the treatment of infectious diseases,...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Antibiotic Studies Accepted for Presentation at ICAAC
August 21, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Aug. 21, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Reports Second Quarter 2012 Financial Results
August 09, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., Aug. 9, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix and University of Pennsylvania Collaborate to Develop New Class of Defensin-Mimetic Antimicrobial Compounds to Treat Malaria
July 31, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., July 31, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Outlines Potential Benefits of GAIN Act to Its Antibiotic Development Program
July 13, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., July 13, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Receives USAN Approval for Generic Name of Brilacidin for PMX-30063
June 12, 2012 16:30 ET
|
PolyMedix, Inc.
RADNOR, Pa., June 12, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
New Data on PMX-30063 Presented at ASCO Suggest Strong Potential as Treatment for Oral Mucositis
June 04, 2012 07:00 ET
|
PolyMedix, Inc.
RADNOR, Pa., June 4, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Provides Update on PMX-60056 Program
May 10, 2012 17:01 ET
|
PolyMedix, Inc.
RADNOR, Pa., May 10, 2012 (GLOBE NEWSWIRE) -- PolyMedix, Inc. (OTCBB:PYMX), a biotechnology company focused on developing innovative therapeutic drugs to treat patients with serious acute-care...
![PolyMedix, Inc. Logo](/news-release/logo/213869/0/213869.jpg?lastModified=12%2F10%2F2016%2000%3A36%3A16&size=2)
PolyMedix Announces Positive Results From Phase 2 Clinical Trial With PMX-30063 First-in-Class Defensin-Mimetic Antibiotic
April 23, 2012 07:00 ET
|
PolyMedix, Inc.
Study in patients with Acute Bacterial Skin and Skin Structure Infections showed all three doses to have high clinical response rates and to be safe
Conference Call Today at 9:00 a.m....